Late-Breaking Clinical Trials
The ACC is no longer accepting Late-Breaking Clinical Trial submissions. Accepted submissions will be featured at ACC.22, where presenters will share their science with colleagues from around the world, and debate and discuss the outcomes with a panel of global thought-leaders.
Late-Breaking Clinical Trials were accepted in the following categories:
- Major Study
- Smaller Study/Randomized Clinical Trial
- Multi-center Observational Study or Registry
- Secondary Analysis of Major Clinical Trial
Accepted Late-Breaking Clinical Trial submissions will be presented during one of five Late-Breaking Clinical Trial sessions in the Main Tent in Washington, DC and streamed live on the ACC.22 virtual platform. Three LBCT sessions will be co-sponsored by the Journal of the American College of Cardiology (JACC), the Journal of the American Medical Association (JAMA) and the New England Journal of Medicine (NEJM). Each accepted submission will be considered for JACC Rapid Review and publication in JACC, JAMA and NEJM. In addition, each LBCT session will be followed by a press conference with top media outlets.
| 2021 American College of Cardiology Foundation. Visit ACC.org|